(19)
(11) EP 1 210 948 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.07.2007 Bulletin 2007/27

(45) Mention of the grant of the patent:
25.04.2007 Bulletin 2007/17

(21) Application number: 00957052.4

(22) Date of filing: 08.09.2000
(51) International Patent Classification (IPC): 
A61K 38/08(2006.01)
A61P 25/00(2006.01)
A61P 21/04(2006.01)
 A61P 25/28(2006.01)
A61P 21/02(2006.01)
A61P 43/00(2006.01)
(86) International application number:
PCT/JP2000/006150
(87) International publication number:
WO 2001/017545 (15.03.2001 Gazette 2001/11)

(54)

THERAPEUTIC PEPTIDE FOR NERVOUS DISEASES

PEPTID ZUR BEHANDLUNG VON NERVENERKRANKUNGEN

PEPTIDE POUR LA THERAPIE DES MALADIES NERVEUSES

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 09.09.1999 JP 25515999

(43) Date of publication of application:
05.06.2002 Bulletin 2002/23

(73) Proprietor: NIPPON CHEMIPHAR CO., LTD.
Tokyo 101-8678 (JP)

(72) Inventors:
  • NISHIKAWA, Takashige
    Kagoshima-shi,Kagoshima 890-0073 (JP)
  • HIRATE, Kenji
    Kasukabe-shi, Saitama 344-0025 (JP)

(74) Representative: Albrecht, Thomas et al
Kraus & Weisert, Thomas-Wimmer-Ring 15
80539 München
80539 München (DE)


(56) References cited: : 
EP-A1- 0 393 934
 JP-A- 11 171 786
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).